SELLAS Logo.png
SELLAS Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Update
13 août 2024 16h10 HE | SELLAS Life Sciences Group, Inc.
- Announced Independent Data Monitoring Committee’s (IDMC) Recommendation to Continue the Phase 3 REGAL Study in Patients with Acute Myeloid Leukemia (AML) Without Modifications: Interim Analysis...
SELLAS Logo.png
SELLAS Receives EMA Orphan Drug Designation for SLS009 for Treatment of Peripheral T-cell Lymphomas
06 août 2024 08h45 HE | SELLAS Life Sciences Group, Inc.
NEW YORK, Aug. 06, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of...
SELLAS Logo.png
SELLAS Life Sciences Announces $21.0 Million Registered Direct Offering Priced at a Premium to Market
31 juil. 2024 08h30 HE | SELLAS Life Sciences Group, Inc.
NEW YORK, July 31, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of...
SELLAS Logo.png
SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to SLS009 for the Treatment of Pediatric Acute Myeloid Leukemia
16 juil. 2024 09h05 HE | SELLAS Life Sciences Group, Inc.
- Acute Myeloid Leukemia (AML) is the Second Most Common Hematological Malignancy in Children Often Associated with Poorer Prognosis Compared to Other Pediatric Cancers – - This Recognition Marks...
SELLAS Logo.png
SELLAS Receives European Medicines Agency Orphan Drug Designation for SLS009 for the Treatment of Acute Myeloid Leukemia
08 juil. 2024 08h45 HE | SELLAS Life Sciences Group, Inc.
NEW YORK, July 08, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of...
SELLAS Logo.png
SELLAS Announces U.S. FDA Rare Pediatric Disease Designation Granted to SLS009 for the Treatment of Pediatric Acute Lymphoblastic Leukemia
24 juin 2024 09h05 HE | SELLAS Life Sciences Group, Inc.
- Acute Lymphoblastic Leukemia (ALL) is the Most Common Type of Cancer in Children – - Rare Pediatric Disease Designation (RPDD) Provides Eligibility for SLS009 to Receive a Priority Review Voucher...
SELLAS Logo.png
SELLAS Life Sciences Announces Positive Recommendation from the Independent Data Monitoring Committee of the Phase 3 REGAL Trial in Acute Myeloid Leukemia
17 juin 2024 09h05 HE | SELLAS Life Sciences Group, Inc.
–  The Independent Data Monitoring Committee (IDMC) Recommends Continuation of Phase 3 REGAL Trial Without Any Modifications – –  No Safety or Futility Concerns Were Raised Based on the Efficacy...
SELLAS Logo.png
SELLAS Announces Completion of Enrollment and Initial Positive Data in Phase 2a Trial of SLS009 in r/r AML
10 juin 2024 08h40 HE | SELLAS Life Sciences Group, Inc.
- 30 Patients Relapsed or Refractory to Venetoclax-Based Regimens Enrolled Ahead of Schedule - - Overall Response Rate (ORR) of 33% and 50% Achieved to Date in 60 mg QW and 30 mg BIW Cohorts,...
SELLAS Logo.png
SELLAS Life Sciences Reports First Quarter 2024 Financial Results and Provides Corporate Update
14 mai 2024 16h05 HE | SELLAS Life Sciences Group, Inc.
- Announced Independent Data Monitoring Committee’s (IDMC) Recommendation to Continue the Phase 3 REGAL Study in Patients with Acute Myeloid Leukemia (AML) Without Modifications: IDMC to Reconvene in...
SELLAS Logo.png
SELLAS Announces Positive Phase 2 Preliminary Data of SLS009 in r/r AML Achieving a 100% Response Rate in Patients with ASXL1 Mutation At the Optimal Dose Level
01 mai 2024 08h35 HE | SELLAS Life Sciences Group, Inc.
- The Company Filed IP Protection Related to the ASXL1 Mutation, a Highly Prevalent Gene Mutation in Myeloid Malignancies and Solid Tumors With Significant Market Potential – - 100% Overall...